A recent analysis from the STEP-HFpEF program showed that semaglutide compared with placebo reduced NT-proBNP at 52 weeks (estimated treatment ratio: 0.82; 95% CI: 0.74–0.91; p = 0.0002) and participants with higher baseline NT-proBNP had a similar degree of weight loss but experienced larger reductions in HF-related symptoms and physical limitations with semaglutide than those with lower NT-proBNP [28]. The gene discussed is NPPB; the disease is hydrops fetalis.